Latest in Mental Health

Nano CBD: Cannabidiol made with the human body in mind

Infinite CBD's Ali Munk explains how CBD products work, and why choosing nanotechnology as drug delivery increases its bioavailability

Find out more

FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing

A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with...
See more

GW Pharmaceuticals gains product recognition by NHS England

Epidyolex (cannabidiol) oral solution and Sativex (nabiximols) have been recommended for use by the UK’s National Institute for Health and Care Excellence

AC Immune and Lilly announce licence and collaboration agreement

Multi-year agreement focuses on Morphomer tau aggregation inhibitors, for the potential treatment of Alzheimer's disease and other neurodegenerative diseases

Axol Bioscience launches human iPSC-derived microglia

A reproducible, physiologically relevant cellular model of human microglia for neurodegenerative disease drug discovery and development

New approaches to treat psychiatric disorders

Cardiff University forms new drug discovery collaboration for psychiatric disorders

Personalised medication is becoming an increasing possibility for patients

A long sought after objective of healthcare is to ensure that each patient receives tailored treatment for their medical situation

Antiepileptic drugs increase risk of Alzheimer’s and dementia

The use of antiepileptic drugs is associated with an increased risk of Alzheimer’s disease and dementia, according to a new study from the University of Eastern Finland and the German Center for Neurodegenerative Diseases, DZNE

In search of a biomarker

Altered bacterial communities in the gut could be an indicator for Parkinson’s disease

Simplifying continuous operations: lowering the barrier to faster development

Continuous manufacturing has long promised faster development, improved process understanding and, in the absence of scale-up, smoother commercialization. For many pharmaceutical R&D teams, those benefits are well understood. What still holds them back, however, is not scepticism about the concept; it’s the perceived effort required to implement it

Latest posts in Mental Health

Invent Farma/neuraxpharm Group announces the acquisition of FB Health in Italy

The Invent Farma/neuraxpharm Group, a leading specialty generics company focussed on CNS, has announced the acquisition of FB Health, an Italy based specialty pharma company focused on neurology and psychiatry

Leading charity calls for government to confirm plans for dementia research

Alzheimer's Research UK’s call comes amid speculation that the Great Repeal Bill – aimed at ensuring EU law will no longer apply in the UK after Brexit – could see other issues fall from the political agenda

New schizophrenia drug may improve patient compliance

RBP-7000, new pipeline novel sustained-release drug by Indivior, showed patients “stable or improved” throughout test period

Valproate and docetaxel under scrutiny from EMA Committee

The Pharmacovigilance Risk Assessment Committee (PRAC) reviewed valproate and docetaxel-containing medicines for safety in treating pregnant woman and cancer sufferers

Merz outsources its compound management to BioAscent

BioAscent supplies screening plates on demand to provide flexible and cost-effective management of solid and liquid compounds

Benzodiazepines and related drugs increase stroke risk among persons with Alzheimer’s disease

The use of benzodiazepines and benzodiazepine-like drugs was associated with a 20% increased risk of stroke among persons with Alzheimer’s disease, shows a recent study from the University of Eastern Finland

Alzheimer’s advance: early stage study in mice show new drugs that restore memory loss and prolong life

Breakthrough findings demonstrate a possible target and potential drug treatment to restore memory loss and extend life span in mice with neurodegeneration

Director announced to lead UK Dementia Research Institute in London

The director of the UK Dementia Research Institute (UK DRI) has been named as Professor Bart De Strooper, current leader of the Laboratory for the Research of Neurodegenerative Diseases at the University of Leuven and scientific director at VIB (Vlaams Instituut voor Biotechnologie) in Belgium. Professor De Strooper will lead the national institute from UCL

Schizophrenia treatment urgently requires drugs targeting negative symptoms

The schizophrenia market across the seven major markets of the US, France, Germany, Italy, Spain, the UK and Japan is set to rise from $6.4 billion in 2015 to $7.3 billion by 2025, registering a compound annual growth rate of 1.4%, according to research and consulting firm GlobalData
You need to be a subscriber to read this article.
Click here to find out more.

Alzheimer’s disease: a new therapeutic strategy

Probiodrug’s novel approach to Alzheimer’s targets a modified form of ß-amyloid, which has a key role in the formation of toxic Aß oligomers. The company’s lead product is a first-in-class oral small molecule glutaminyl cyclase inhibitor

ADHD market to reach $13.9bn by 2024 as awareness increases and drugs improve

Late-stage pipeline treatments are anticipated to be a key driver in the ADHD market

Sponsor content

Antidepressant use increases risk of head injuries among persons with Alzheimer’s disease

Antidepressant use is associated with an increased risk of head injuries and traumatic brain injuries among persons with Alzheimer’s disease, according to a new study...

Cypralis Limited announces grant award

Cypralis, a life sciences company focussed on the discovery of therapeutics for the modulation of peptidyl-prolyl isomerases (PPIases), has been awarded funding of...

Alkermes to initiate second Phase III study of ALKS 3831 for schizophrenia

ENLIGHTEN-2 will evaluate weight gain profile of novel, once-daily, oral investigational medicine compared with olanzapine

Alkermes submits NDA to FDA for aripiprazole lauroxil for treatment of schizophrenia

Potential to be novel once-monthly product for schizophrenia with differentiated profile, including ready-to-use format and multiple dose strengths

Alkermes initiates FORWARD-5 clinical study of ALKS 5461

All three core efficacy studies in FORWARD pivotal programme now underway for treatment of major depressive disorder

Alkermes to present data on new medicines in development for schizophrenia and depression

Results of positive Phase 3 study for aripiprazole lauroxil in schizophrenia to be presented at upcoming American Society of Clinical Psychopharmacology Annual Meeting